Mar 27 |
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
|
Mar 26 |
Rocket Pharmaceuticals appoints Aaron Ondrey as CFO
|
Mar 26 |
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
|
Mar 1 |
Rocket Pharmaceuticals' Promising Path In Gene Therapy
|
Feb 27 |
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
|
Feb 26 |
Rocket Pharmaceuticals GAAP EPS of -$0.64 beats by $0.14
|
Feb 26 |
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
|
Feb 13 |
15 Best Strong Buy Stocks To Invest In
|
Feb 13 |
FDA extends review period for Rocket gene therapy to June 30
|
Feb 13 |
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
|